Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease

20 May 2022

Abstract excerpt

Although the epigenetic regulatory protein histone deacetylase 6 (HDAC6) has been recently implicated in the etiology of Alzheimer's disease (AD), little is known about the role of HDAC6 in the etiopathogenesis of AD and whether HDAC6 can be a potential therapeutic target for AD. Here, we performed positron emission tomography (PET) imaging in combination with histopathological analysis to better understand the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36213537
DOI: 10.1016/j.apsb.2022.05.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a potential PET probe for HDAC6 imaging in Alzheimer's diseasePMID 36213537Read ↗

The Role of HDAC6 in Alzheimer's DiseaseSemantic proximity Read ↗

Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agentsSemantic proximity Read ↗

Targeting HDACs: A Promising Therapy for Alzheimer's DiseaseSemantic proximity Read ↗

Histone Deacetylase Inhibition in Alzheimer’s Disease: Molecular Mechanisms, Therapeutic Potential, and Future PerspectivesSemantic proximity Read ↗

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Semantic proximity Read ↗

HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological DisordersSemantic proximity Read ↗

Imaging brain class I histone deacetylase changes in the Lewy body dementias and Parkinson’s diseaseSemantic proximity Read ↗

HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative DiseaseSemantic proximity Read ↗

Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's diseaseSemantic proximity Read ↗

Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the Alzheimer's disease mouse model by regulating the expression of App secretasesSemantic proximity Read ↗

Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

High-Contrast PET imaging with [ <sup>18</sup> F]-NT160, a Class-IIa Histone Deacetylase (Class-IIa HDAC) Probe for In Vivo Imaging of Epigenetic Machinery in the Central Nervous SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.